External validity of the international method for predicting clinical outcome of immunoglobulin A-nephropathy in the Belarusian cohort of patients

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. Assessment of the external validity of the International Method for Predicting the Clinical Outcome of Immunoglobulin A Nephropathy (IGAN) based on an independent Belarusian cohort of patients.

Material and methods: The study included 164 patients with a confirmed diagnosis of IgAN in the Nephrology Departments of Minsk. For the period from 2010 to 2020, the predicted risks of clinical outcome for each patient in the Belarusian cohort were calculated. The effectiveness of discrimination (Harrell's C-index of concordance, Royston-Sauerbrey discrimination coefficient R2D, and Kaplan-Meier curves between subgroups) and model calibration (calibration slope) were assessed.

Results. The international method showed excellent discrimination (Harrell C-index=0.86, R2D=60% and well-separated survival curves between low- and high-risk patients), satisfactory calibration (calibration slope >1.2) regardless of the inclusion of a race model.

Conclusion. The study demonstrated high discrimination and satisfactory calibration of the international method for predicting the clinical outcome of IgAN in the Belarusian cohort of patients

Толық мәтін

Рұқсат жабық

Авторлар туралы

Kirill Komissarov

State University Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology; Institute for Advanced Training and Retraining of Healthcare Personnel, Belarusian State Medical University

Хат алмасуға жауапты Автор.
Email: kirill_ka@tut.by
ORCID iD: 0000-0002-2648-0642

Cand.Sci. (Med.), Associate Professor, Head of the Department of Nephrology, Renal Replacement Therapy and Kidney Transplantation, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology

Белоруссия, Minsk; Minsk

Olga Krasko

Joint Institute of Informatics Problems of the National Academy of Sciences of Belarus

Email: olga.krasko.ok@gmail.com
ORCID iD: 0000-0002-4150-282X

Cand.Sci. (Tech.), Leading Researcher at the Laboratory of Bioinformatics Joint Institute of Informatics Problems of the National Academy of Sciences of Belarus

Белоруссия, Minsk

Valery Pilotovich

Institute for Advanced Training and Retraining of Healthcare Personnel, Belarusian State Medical University

Email: pilotovich@mail.ru
ORCID iD: 0000-0001-8256-5889

Dr.Sci. (Med.), Professor at the Department of Urology and Nephrology, Institute for Advanced Training and Retraining of Healthcare Personnel

Белоруссия, Minsk

Margarita Dmitrieva

Belarusian State Medical University; City Clinical Pathological Bureau

Email: mvdmitieva@inbox.ru
ORCID iD: 0000-0002-2958-9424

Associate Professor at the Department of Pathological Anatomy

Белоруссия, Minsk; Minsk

Tatyana Letkovskaya

Belarusian State Medical University

Email: taletkovskaya@mail.ru
ORCID iD: 0000-0002-9381-2985

Associate Professor, Head of the Department of Pathological Anatomy

Белоруссия, Minsk

Sergey Prilutsky

Minsk Regional Clinical Hospital

Email: 2489861@rambler.ru
ORCID iD: 0009-0004-5174-1893

Nephrologist, Head of the Hemodialysis Department

Белоруссия, Minsk

Әдебиет тізімі

  1. Pattrapornpisut P., Avila-Casado C., Reich H.N. IgA Nephropathy: Core Curriculum 2021. Am. J. Kidney Dis. 2021;78(3):429–41. doi: 10.1053/j.ajkd.2021.01.024.
  2. O’Shaughnessy M.M., Hogan S.L., Thompson B.D., et al. Glomerular disease frequencies by race, sex and region: Results from the International Kidney Biopsy Survey. Nephrol. Dial. Transplant. 2018;33(4):661–9. doi: 10.1093/ndt/gfx189.
  3. Комиссаров К.С., Комиссаров К.С., Дмитриева М.В., Летковская Т.А. Гистопатологический спектр болезней почек по данным нефробиопсий, выполненных в Минске, Республика Беларусь. Клин. нефрология. 2020;12(2):26–30. [Komissarov K.S., Komissarov K.S., Dmitrieva M.V., Letkovskaja T.A. Histopathological spectrum of kidney diseases according to nephrobiopsies performed in Minsk, Republic of Belarus. Clin. Nephrol. 2020;12(2):26–30 (In Russ.)].
  4. Комиссаров К.С., Валовик О.E., Дмитриева М.В. и др. Эпидемиология первичного гломерулонефрита по данным нефробиопсий в г. Минске, Республика Беларусь. Нефрология и диализ. 2011;13(3):358. [Komissarov K.S., Valovik O.E., Dmirieva M.V., Budanova S.V., Pilotovich V.S. Epidemiology of primary glomerulonephritis on results of nephrobiosies performed Minsk, Republic Belarus. Nephrol. Dial. 2011;13(3):358 (In Russ.)].
  5. Комиссаров К.С., Краско О.В., Дмитриева М.В. и др. Иммуноглобулина А – нефропатия в белорусской когорте. Клинико-морфологические особенности, факторы, ассоциированные с неблагоприятным исходом. Клин. нефрология. 2022;3:25–33. [Komissarov K.S., Krasko O.V., Dmitrieva M.V., et al. IgA nephropathy in Belarusian cohort. Сlinical and pathological peculiarities, factors, associated with unfavorable outcome. Clin. Nephrol. 2022;3:25–33 (In Russ.)].
  6. Barbour S.J., Coppo R., Zhang H., et al. Evaluating a new international risk-prediction tool in iga nephropathy. JAMA. Intern. Med. 2019;179:942–52. doi: 10.1001/jamainternmed.2019.0600.
  7. Barbour S. Personalised risk stratification in IgAN – is it possible? Kidney Dis. 2018;4:145–6. doi: 10.1159/000492807.
  8. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006.
  9. Cattran D., Coppo R., Cook H., et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45. doi: 10.1038/ki.2009.243.
  10. Trimarchi H., Barratt J., Cattran D., et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014–21. doi: 10.1016/j.kint.2017.02.003.
  11. Zhang Y., Guo L., Wang Z., et al. External validation of international risk-prediction models of iga nephropathy in an asian-caucasian cohort. Kidney Int. Rep. 2020;5:1753–63. doi: 10.1016/j.ekir.2020.07.036.
  12. Royston P., Altman D.G. External validation of a cox prognostic model: principles and methods. BMC. Med. Res. Methodol. 2013;13:33. doi: 10.1186/1471-2288-13-33.
  13. Royston P., Sauerbrei W. A new measure of prognostic separation in survival data. Stat. Med. 2004;23:723–48. doi: 10.1002/sim.1621.
  14. Harrell F.E., Califf R.M., Prior D.B., et al. Evaluating the yield of medical tests. J. Am. Med. Assoc. 1982;247:2543–6.
  15. Cohen J. Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychol. Bull. 1968;70(4):213–20. doi: 10.1037/h0026256.
  16. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2023. URL https://www.R-project.org.
  17. Okonogi H., Utsunomiya Y., Miyazaki Y., et al, A predictive clinical grading system for immunoglobulin A nephropathy by combining proteinuria and estimated glomerular filtration rate. Nephron Clin. Pract. 2011;118(3):292–300. doi: 10.1159/000322613.
  18. Pesce F., Diciolla M., Binetti G., et al. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrol. Dial. Transplant. 2016;31(1):80–6. doi: 10.1093/ndt/gfv232.
  19. Chen T., Li X., Li Y., et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy. Am. J. Kidney Dis. 2019;74(3):300–9. doi: 10.1053/j.ajkd.2019.02.016.
  20. Tripepi G., Heinze G., Jager K.J., et al. Risk prediction models. Nephrol. Dial. Transplant. 2013;28(8):1975–80. doi: 10.1093/ndt/gft095.
  21. Bon G., Jullien P., Masson I., et al. Validation of the international IgA nephropathy prediction tool in a French cohort beyond 10 years after diagnosis. Nephrol. Dial. Transplant. 2023;38:2257–65. doi: 10.1093/ndt/gfad048.
  22. Papasotiriou M., Stangou M., Chlorogiannis D., et al. Validation of the international IgA nephropathy prediction tool in the Greek Registry of IgA nephropathy. Front. Med. 2022;9:article 778464. doi: 10.3389/fmed.2022.778464.
  23. Collins G.S., Ogundimu E.O., Altman D.G. Sample size considerations for the external validation of a multivariable prognostic model: A resampling study. Stat. Med. 2016;35(2):214–26. doi: 10.1002/sim.6787.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Patient selection design for the study

Жүктеу (61KB)
Метадеректер
3. Fig. 2. Kaplan-Meier curves indicating the probability of survival from the primary outcome in 4 groups based on linear regression percentiles, where A is the LPR-E model, and B is the LPR+E model.

Жүктеу (367KB)
Метадеректер

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>